|
|
 | ||||
 Strong Alliance and All-Win Collaboration | ||||
|  |
|
 | |
| ||||
| In order to pool scientific research resources and realize the complementary integration of production, learning and research advantages, relying on the solid Traditional Chinese Medicinal research of Nanjing University of Traditional Chinese Medicine, and also the excellence on Ion Channels and Electrophysiology of Nanjing Amazigh Pharma Limited. A Strategic Collaboration Agreement on jointly establishing "R & D Center of Ion Channel-Targeted Innovation Drug" was signed by Nanjing Amazigh Pharma Limited and the Integrated Hospital of Traditional Chinese and Western Medicine Affiliated to Nanjing University of Traditional Chinese Medicine on August 6, 2021. The establishment of “R & D Center of Ion Channel-Targeted Innovation Drug” has laid a solid foundation for improving the scientific research level of both organizations and promoting the development of Traditional Chinese Medicinal research and biomedical industry in Nanjing. Dr. Li Gui-Rong, Founder/Chairman of Nanjing Amazigh Pharma Limited and Professor Dr. Cao Peng, the National Outstanding Youth of Nanjing University of Traditional Chinese Medicine and the Winner of the first Tu Youyou Traditional Chinese Medicine Innovation Award, signed the Strategic Collaboration Agreement on "R & D Center of Ion Channel-Targeted Drug". The inaugural meeting of the center was presided over by Dr. Cao Meng, the deputy director of the Scientific Research Department, the Integrated Hospital of Traditional Chinese and Western Medicine Affiliated to Nanjing University of Traditional Chinese Medicine. Dr. Fang Zhi-Jun, the vice president for Scientific Research, and all researchers and postgraduates attended the inaugural meeting. Finally, Vice-President Fang awarded Dr. Li Gui-Rong the appointment letter as a Visiting Investigator in the Integrated Hospital of Traditional Chinese and Western Medicine Affiliated to Nanjing University of Traditional Chinese Medicine. | | ||
| ||||
Global Market of Anti-atrial Fibrillation Drugs | |
It is reported that by 2023, the market of anti-atrial fibrillation drugs in seven industrial countries plus Spain is estimated to be 5.7 billion US dollars, excluding the market in China, India, Russia, Southeast Asia, the Middle East, Africa and other countries in the world. |
 |
 | |